David MBA - Salarius Pharmaceuticals President CEO

SLRX Stock  USD 1.45  0.07  4.61%   

CEO

David MBA is President CEO of Salarius Pharmaceuticals
Age 61
Address 2450 Holcombe Boulevard, Houston, TX, United States, 77021
Phone832 834 9144
Webhttps://www.salariuspharma.com

Salarius Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.5399) % which means that it has lost $0.5399 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1983) %, meaning that it created substantial loss on money invested by shareholders. Salarius Pharmaceuticals' management efficiency ratios could be used to measure how well Salarius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.002 in 2024. Return On Capital Employed is likely to drop to -0.0026 in 2024. At this time, Salarius Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Total Assets are likely to drop slightly above 6.3 M in 2024.
Salarius Pharmaceuticals currently holds 289.64 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Salarius Pharmaceuticals has a current ratio of 8.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Salarius Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 6 records

CEO Age

LLM JDTempest Therapeutics
54
Joseph MBAMilestone Pharmaceuticals
56
Mark ManfrediIkena Oncology
53
BAO BChEliem Therapeutics
48
John TuckerScpharmaceuticals
61
Eric MBASeres Therapeutics
48
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. Salarius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. Salarius Pharmaceuticals (SLRX) is traded on NASDAQ Exchange in USA. It is located in 2450 Holcombe Boulevard, Houston, TX, United States, 77021 and employs 2 people. Salarius Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Salarius Pharmaceuticals Leadership Team

Elected by the shareholders, the Salarius Pharmaceuticals' board of directors comprises two types of representatives: Salarius Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Salarius. The board's role is to monitor Salarius Pharmaceuticals' management team and ensure that shareholders' interests are well served. Salarius Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Salarius Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark CPA, Executive CFO
Daniela Santiesteban, Director Program
David MBA, President CEO
MPH MD, Senior Development

Salarius Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Salarius Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.